In a significant development for shareholders of MacroGenics, Inc. (NASDAQ: MGNX), the law firm Robbins Geller Rudman & Dowd LLP has announced the initiation of a class action lawsuit against the company and its Chief Executive Officer for alleged violations of the Securities Exchange Act of 1934. This follows a tumultuous period for the biopharmaceutical firm, known for its focus on innovative antibody-based therapeutics for cancer treatment, and raises important questions for current and potential investors in the company.
Class Action Lawsuit Announcement’
According to the press release from Robbins Geller Rudman & Dowd LLP, investors who purchased MacroGenics stock or sold puts during the class period, which extends from March 7, 2024, to May 9, 2024, have until September 24, 2024, to seek appointment as lead plaintiff in a class action lawsuit
Comments